Status:
COMPLETED
CAR-T Cell Therapy in Patients With Hematological Malignancies
Lead Sponsor:
Grupo Espanol de trasplantes hematopoyeticos y terapia celular
Conditions:
CART Therapy
Eligibility:
All Genders
Brief Summary
The prognosis of relapsed or refractory lymphoblastic leukaemia (ALL) and diffuse large B-cell lymphoma (DLBCL) is poor with conventional treatment with complete response rates around 25-30% with a me...
Detailed Description
Information on baseline patient characteristics, haematological disease, comorbidities and CAR-T therapy procedure (lymphodepletion schedule, infused product) will be collected. Early post-infusion to...
Eligibility Criteria
Inclusion
- Adult patients \>18 y/o
- Patients receiving CAR-T cell therapy in Spain, since 2018.
Exclusion
- T
- Patients receiving CART therapy as part of a clinical trial.
Key Trial Info
Start Date :
November 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2021
Estimated Enrollment :
260 Patients enrolled
Trial Details
Trial ID
NCT05390671
Start Date
November 1 2020
End Date
June 1 2021
Last Update
June 1 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Angel Cedillo
Madrid, Spain